

Farmacoeconomia La Valutazione Economica Dei Farmaci

Thank you entirely much for downloading **Farmacoeconomia La Valutazione Economica Dei Farmaci** .Most likely you have knowledge that, people have see numerous period for their favorite books in the same way as this Farmacoeconomia La Valutazione Economica Dei Farmaci , but end stirring in harmful downloads.

Rather than enjoying a good ebook later than a cup of coffee in the afternoon, on the other hand they juggled taking into consideration some harmful virus inside their computer.

Farmacoeconomia La Valutazione Economica Dei Farmaci is manageable in our digital library an online access to it is set as public appropriately you can download it instantly. Our digital library saves in combined countries, allowing you to acquire the most less latency time to download any of our books next this one. Merely said, the Farmacoeconomia La Valutazione Economica Dei Farmaci is universally compatible like any devices to read.

Dialoghi sulla sostenibilità. Roma 2016 -

CRUL - Comitato Regionale di Coordinamento delle Università del Lazio 2016-09-01

Il volume Dialoghi sulla Sostenibilità - Roma 2016 raccoglie gli Atti di quattro convegni progettati dagli Atenei del Lazio, coordinati dal CRUL (Comitato Regionale di Coordinamento delle Università del Lazio) - in occasione del Giubileo Straordinario 2015-2016 - per discutere di sostenibilità a partire dalle diverse esperienze e consapevolezze maturate dalle Università regionali. I 'Dialoghi' rappresentano studi, tratteggiano visioni, suscitano domande sul futuro della nostra società e del nostro ambiente. In occasione di questi confronti pubblici, il mondo della conoscenza e della ricerca, indipendentemente dalle istituzioni di provenienza, ha cercato di elaborare, in collaborazione e in modo coerente, un contributo sintetico ma esatto, da offrire alla società civile. *Architettura aziendale* - Maria Pilar Vettori 2013

To Err Is Human - Institute of Medicine 2000-03-01

Experts estimate that as many as 98,000 people die in any given year from medical errors that occur in hospitals. That's more than die from motor vehicle accidents, breast cancer, or AIDS"three causes that receive far more public attention. Indeed, more people die annually from medication errors than from

workplace injuries. Add the financial cost to the human tragedy, and medical error easily rises to the top ranks of urgent, widespread public problems. To Err Is Human breaks the silence that has surrounded medical errors and their consequence"but not by pointing fingers at caring health care professionals who make honest mistakes. After all, to err is human. Instead, this book sets forth a national agenda"with state and local implications"for reducing medical errors and improving patient safety through the design of a safer health system. This volume reveals the often startling statistics of medical error and the disparity between the incidence of error and public perception of it, given many patients' expectations that the medical profession always performs perfectly. A careful examination is made of how the surrounding forces of legislation, regulation, and market activity influence the quality of care provided by health care organizations and then looks at their handling of medical mistakes. Using a detailed case study, the book reviews the current understanding of why these mistakes happen. A key theme is that legitimate liability concerns discourage reporting of errors"which begs the question, "How can we learn from our mistakes?" Balancing regulatory versus market-based initiatives and public versus private efforts, the Institute of Medicine presents wide-

ranging recommendations for improving patient safety, in the areas of leadership, improved data collection and analysis, and development of effective systems at the level of direct patient care. To Err Is Human asserts that the problem is not bad people in health care "it is that good people are working in bad systems that need to be made safer. Comprehensive and straightforward, this book offers a clear prescription for raising the level of patient safety in American health care. It also explains how patients themselves can influence the quality of care that they receive once they check into the hospital. This book will be vitally important to federal, state, and local health policy makers and regulators, health professional licensing officials, hospital administrators, medical educators and students, health caregivers, health journalists, patient advocates "as well as patients themselves. First in a series of publications from the Quality of Health Care in America, a project initiated by the Institute of Medicine

Costi sociali e aspetti farmaco-economici - M.P. Amato 2006-01-17

La sclerosi multipla (SM) rappresenta la seconda causa di disabilità neurologica nel giovane adulto, dopo i traumi cranici. Negli ultimi anni, l'introduzione di nuovi farmaci, potenzialmente in grado di modificare il decorso della malattia, ha richiamato l'attenzione sui costi sociali della SM e sugli aspetti farmaco-economici. Si sono avanziati, da un lato, timori che il costo dei nuovi farmaci costituisca un onere insostenibile per il sistema sanitario. Dall'altro lato, recenti studi economici hanno sottolineato l'importanza di una valutazione inserita in una prospettiva più ampia, considerando la possibilità che le nuove terapie possano ridurre i costi sociali di malattia nel lungo termine, ritardando o evitando lo sviluppo di invalidità. Questo volume rivede la letteratura internazionale sui costi sociali della SM, e gli studi farmaco-economici sui nuovi farmaci per la malattia. In futuro, sarà necessario implementare studi metodologicamente rigorosi, in particolare di tipo comparativo. Estremamente importante sarà la raccolta di dati prospettici su ampie popolazioni di pazienti, per valutare il reale impatto delle nuove terapie sullo sviluppo di disabilità a lungo termine. Le informazioni

attualmente disponibili derivano infatti essenzialmente dalle sperimentazioni terapeutiche, che si riferiscono a casistiche selezionate di pazienti seguiti per brevi periodi (2-3 anni). L'acquisizione di questi dati sarà di importanza critica per migliorare la stima del rapporto costi/benefici con l'impiego dei nuovi farmaci e valutare le priorità in politica sanitaria negli anni a venire.

Il dolore. Valutazione, diagnosi e trattamento - Sebastiano Mercadante 2005

A review of UK health research funding - Sir David Cooksey 2006-12-06

This Review sets out to propose a structure for the funding arrangements for the whole spectrum of health research, with the objective of obtaining the maximum benefit from research success and, where possible, eliminating duplication of effort. The Review found, however, that the UK is at risk of failing to reap the full economic, health and social benefits that the UK's public investment in health research should generate. There is no overarching UK health research strategy to ensure UK health priorities are considered through all types of research and there are two key gaps in the translation of health research: (i) translating ideas from basic and clinical research into the development of new products and approaches to treatment of disease and illness; (ii) implementing those new products and approaches into clinical practice. The Review also found that the wider funding arrangements for supporting translation of ideas from conception to practice could be more coherent or comprehensive and, where arrangements exist, they do not function well. The Review identified cultural, institutional and financial barriers to translating research into practice in the publicly funded research arena. But it also found that, in the private sector, the pharmaceuticals industry is facing increasing challenges in translating research into health and economic benefit. The Review has sought to make recommendations that will increase the translation of R&D into health and economic benefit for the UK, both in the public and private sectors. The Review recommends that the Government should seek to achieve better coordination of health research and more

coherent funding arrangements to support translation by establishing an Office for Strategic Coordination of Health Research (OSCHR).

Control of Cancer Pain - 1987

Evidence-based Pharmacy - Christine Bond 2000

Discusses the extended role of community pharmacists, and presents research evidence to demonstrate the benefits of these new services.

Oxford Textbook of Public Health - Roger Detels 2009

This fifth edition of the ever-popular Oxford Textbook of Public Health Practice has been thoroughly updated, and remains the ultimate resource on the subject of public health and epidemiology. Two new editors, Mary Ann Lansang and Martin Gulliford, join the established editor team of Roger Detels and Robert Beaglehole, representing a truly global outlook from four continents. The contributors are drawn from across the world, offering perspectives from vastly different health systems, with ranging public health needs and priorities. With contributors including Dr. Margaret Chan, Director of the World Health Organization, this book offers a globally comprehensive picture of modern health. The book retains its approach of dividing the complex, dynamic subject of public health into three topics. First, the scope of public health is covered, looking at the development of the discipline, determinants of health and disease, public health policies, and laws and ethics. The second volume focuses on the methods of public health, including the main science behind the discipline--epidemiology. Finally, the third volume puts the theory into practice, examining specific public health problems and options for prevention and control. As well as identifying these issues by system or disease, there is also an awareness of the unique needs of particular population groups. The book concludes with an analysis of the functions of public health, and a look at the future of public health in the 21st century. The picture of world health has moved on dramatically since the publication of the fourth edition in 2002. This new edition includes substantial new material on the impact of private support of public health; globalization; water and sanitation; leadership; community-

intervention trials; disease and infection; gene environment interactions; obesity and physical inactivity; urbanization; minorities and indigenous populations; health needs assessment; clinical epidemiology, and the practice of public health. This ensures that the Oxford Handbook of Public Health Practice remains the most comprehensive, accessible text for both students and practitioners in public health and epidemiology.

Farmacoeconomia in pratica - Lorenzo Pradelli 2014-11-14

Le questioni economiche correlate al settore sanitario sono state oggetto di un'attenzione crescente negli ultimi anni e la sfida di fornire un servizio sanitario di qualità e integrale a una popolazione in crescita è diventato sempre più complesso. Lo scopo del libro è quello di presentare ai lettori i principi fondamentali dell'economia e un insieme di strumenti analitici di valutazione economica e la loro applicazione nel settore sanitario. Le tecniche di valutazione più importanti vengono spiegate mediante l'ausilio di esempi: l'analisi di minimizzazione dei costi, l'analisi di costo-efficacia, l'analisi di costo-utilità e l'analisi di costo-beneficio.

Farmacie, farmacisti e anziani. Il farmaco come se la persona contasse - Raffaele Federici 2009

Servizi sanitari. Economia e Management - Guido Citoni 2021-02-01

Il settore sanitario ha una grande rilevanza economica. In esso convivono formule diverse: il pubblico, il privato, il non-profit. La peculiarità del volume è quella di legare la prospettiva economica e quella manageriale. Nell'ambito della prima, l'analisi è condotta sia in ambito micro, per definire le condizioni di efficienza e di efficacia del servizio, sia in ambito macro, per individuare il contributo che il miglioramento delle condizioni di salute dà alla formazione del capitale umano, la cui accumulazione è alla base della crescita economica. Sono altresì affrontati i problemi di policy. Lo schema generale si basa sull'interazione tra domanda e offerta. I sei capitoli sono articolati in una lezione di base ed un ricco apparato di schede (oltre 70).

L'approccio modulare consente l'utilizzo del testo a vari livelli: nei corsi di laurea, nelle lauree specialistiche, nei master; nella Facoltà di Medicina, di Economia, di Ingegneria.

The COVID-19 Pandemic, India and the World - Rajib Bhattacharyya 2021-09-30

This book analyses the economic and social impact of the Covid-19 crisis with special focus on India. It examines the economic disruption caused by the pandemic, policy responses to it and the prospect of a severe global recession. It also covers how the pandemic has contributed to considerable suffering among the masses and affected socio-cultural relationships, behavioural patterns and psychological attitudes governing human interaction. A topical and timely collection on the pandemic, the essays in the volume discuss several key themes which include, · The Corona pandemic and the changing global economy; growth, trade and macroeconomic recovery; · Public health and policy failures; appropriate policy response; · Impact on education; guidelines for the future; · Idea of economic herd immunity; impact of India's lockdown, crisis of the migrant labourers; · Impact on agriculture, industry, firms, households and the informal sector; · Implications of digital technology for production, labour and labour relations; · Violence amidst the virus; Covid 19 and Hindu- Muslim conflict in India, domestic violence, questions of occupation, identity, gender and vulnerability; · De-globalisation and environmental challenges in the post-Covid era. Engagingly written, this comprehensive volume compiles original research by leading economists from India and abroad. It will be useful for scholars and researchers of economics, of the Indian economy, development economics, development studies, labour studies, public policy, public administration, governance, sociology and political economy.

[Il farmaco: ricerca, sviluppo e applicazione in terapia](#) - Ettore Novellino 2019

[Italiano]: Il farmaco: ricerca, sviluppo e applicazione in terapia si propone l'obiettivo di offrire una panoramica sul processo di Ricerca e Sviluppo che un farmaco compie a partire dal momento in cui viene progettato fino alla sua pratica utilizzazione. Quando una molecola è ritenuta potenzialmente adatta per creare un medicinale, si attiva un lungo percorso che ha come traguardo la realizzazione di un nuovo mezzo terapeutico e la sua approvazione per l'immissione in commercio. Un percorso

scandito dalla rigorosa osservanza di regolamenti e leggi che si sono evoluti nel tempo di pari passo con il progresso scientifico e tecnologico, ma spesso anche a seguito di reazioni avverse o eventi dannosi irreversibili che hanno innescato processi di revisione delle norme e dei protocolli sperimentali. Questo libro parte con una densa ricognizione sulla storia della farmacologia occidentale, al fine di agevolare la comprensione del coacervo di vicende e circostanze che nel tempo hanno fatto da sfondo a tutte quelle dinamiche attraverso cui il processo di Ricerca e Sviluppo si è gradualmente affermato e consolidato. Notevole attenzione è stata poi dedicata ad alcuni risvolti divenuti oramai cruciali all'interno dell'articolato universo normativo in cui il farmaco è collocato, quali le terapie avanzate e i nuovi approcci per la ricerca clinica. Inoltre, gli autori si sono concentrati sulla prescrizione dei cosiddetti off-label e sulle tematiche di farmacoutilizzazione e farmacovigilanza che, nel giro di pochi decenni, sono assunte a sfere di conoscenza sempre più significative e influenti nelle prospettive presenti e future, non solo delle scienze farmaceutiche ma dell'intera società. Lo sforzo compiuto per redigere questo volume trova la sua ragion d'essere proprio nel voler mettere a disposizione dei lettori uno sguardo d'insieme sul farmaco e sulle complesse sfide che ancora lo attendono. / [English]: "The drug: research, development and application in therapy" is an in-depth study on the Research and Development process that a drug performs from the moment it is designed up to its practical use. When a molecule is considered suitable for a medicine, a long process is activated which has as its goal the creation of a new therapeutic tool and its approval for marketing. A path marked by the strict observance of regulations and laws that have evolved over time in step with scientific and technological progress. A path that however has often been determined also by tragic events following damaging adverse reactions that have triggered processes of revision of the norms and experimental protocols. This book starts with a summary on the history of Western pharmacology, written to allow the reader to understand the circumstances that have been the background to those dynamics through which the Research and Development process

has gradually consolidated. An important part of the book is dedicated to some aspects that are crucial in the normative universe in which the drug is placed, such as the advanced therapies and new approaches for clinical research. The authors also focused on the prescriptions of off-label drugs and on the issues of pharmacoutilization and pharmacovigilance, two disciplines that, in a few years, have become increasingly influential in the present and future perspectives, not only of the pharmaceutical sciences but of the entire society.

Service Design and Service Thinking in Healthcare and Hospital Management -

Mario A. Pfannstiel 2018-12-28

This book examines the nature of service design and service thinking in healthcare and hospital management. By adopting both a service-based provider perspective and a consumer-oriented perspective, the book highlights various healthcare services, methods and tools that are desirable for customers and effective for healthcare providers. In addition, readers will learn about new research directions, as well as strategies and innovations to develop service solutions that are affordable, sustainable, and consumer-oriented. Lastly, the book discusses policy options to improve the service delivery process and customer satisfaction in the healthcare and hospital sector. The contributors cover various aspects and fields of application of service design and service thinking, including service design processes, tools and methods; service blueprints and service delivery; creation and implementation of services; interaction design and user experience; design of service touchpoints and service interfaces; service excellence and service innovation. The book will appeal to all scholars and practitioners in the hospital and healthcare sector who are interested in organizational development, service business model innovation, customer involvement and perceptions, and service experience.

Ending Medical Reversal - Vinayak K. Prasad 2019-05-14

They outline a comprehensive plan to reform medical education, research funding and protocols, and the process for approving new drugs that will ensure that more of what gets done in doctors' offices and hospitals is truly

effective.

Farmacoeconomia. La valutazione economica dei farmaci - Fabrizio Gianfrate 2015

INDUSTRIA, ITALIA - Riccardo Gallo 2020-09-01

L'industria italiana sta ragionando su cosa fare per superare la terribile caduta provocata dall'epidemia. Alla precedente e meno grave crisi globale del 2008, l'industria aveva risposto con nuove tecnologie, prodotti, riorganizzazione delle fabbriche, acquisizioni e fusioni. Aveva recuperato solo in parte. Con poca guida di politica industriale. Già prima dell'epidemia, il quadro generale stava cambiando. Stava finendo l'era della globalizzazione. La quarta rivoluzione industriale divampava. In Italia, l'occupazione non soffriva numericamente, ma il lavoro si era dequalificato. La fermata del mondo nella primavera del 2020 ha drammatizzato le cose. Sarà difficile per le imprese rispondere a questa caduta con le proprie forze. Sarà erosa la loro liquidità, ma il problema non è finanziario, cioè non si risolve con i soldi pubblici. Il problema è strategico ed esistenziale. Il digitale faciliterebbe il trasferimento tecnologico alle imprese anche piccole e consentirebbe loro di partecipare al progresso. Ma l'Italia è molto indietro anche in questo. Per investire in competenze, ritrovare il valore del merito, recuperare posizioni nel ranking mondiale, occorrerebbero un progetto Competitività serio e di legislatura, e uno qui definito Missionari tecnologici. Con questo volume Sapienza, Università di Roma, offre il suo contributo sociale, culturale ed economico. Il volume è stato curato da Riccardo Gallo, con i contributi di Daniela Addessi, Roberto Adrower, Giuseppe Bonifazi, Marco Bravi, Mario Calabrese, Cinzia Capalbo, Alessandro Corsini, Antonio d'Alessandro, Paolo De Filippis, Luca Di Palma, Fabio M. Frattale Mascioli, Riccardo Gallo, Damiano Garofalo, Carlo Martino, Franco Medici, Francesco Napolitano, Cristiana Piccioni, Daniela Pilone, Massimo Pompili, Antonello Rizzi, Aldo Roveri, Nicola Roveri, Giovanni Solimine.

Pharmageddon - David Healy 2013-04

This searing indictment, David Healy's most comprehensive and forceful argument against the pharmaceuticalization of medicine, tackles

problems in health care that are leading to a growing number of deaths and disabilities. Healy, who was the first to draw attention to the now well-publicized suicide-inducing side effects of many anti-depressants, attributes our current state of affairs to three key factors: product rather than process patents on drugs, the classification of certain drugs as prescription-only, and industry-controlled drug trials. These developments have tied the survival of pharmaceutical companies to the development of blockbuster drugs, so that they must overhype benefits and deny real hazards. Healy further explains why these trends have basically ended the possibility of universal health care in the United States and elsewhere around the world. He concludes with suggestions for reform of our currently corrupted evidence-based medical system.

Annuario delle università degli studi in Italia - 2000

Managing the Risks of Organizational Accidents - James Reason 2016-01-29

Major accidents are rare events due to the many barriers, safeguards and defences developed by modern technologies. But they continue to happen with saddening regularity and their human and financial consequences are all too often unacceptably catastrophic. One of the greatest challenges we face is to develop more effective ways of both understanding and limiting their occurrence. This lucid book presents a set of common principles to further our knowledge of the causes of major accidents in a wide variety of high-technology systems. It also describes tools and techniques for managing the risks of such organizational accidents that go beyond those currently available to system managers and safety professionals. James Reason deals comprehensively with the prevention of major accidents arising from human and organizational causes. He argues that the same general principles and management techniques are appropriate for many different domains. These include banks and insurance companies just as much as nuclear power plants, oil exploration and production companies, chemical process installations and air, sea and rail transport. Its unique combination of principles and

practicalities make this seminal book essential reading for all whose daily business is to manage, audit and regulate hazardous technologies of all kinds. It is relevant to those concerned with understanding and controlling human and organizational factors and will also interest academic readers and those working in industrial and government agencies.

Market Access nel settore healthcare. Strategie, attori, attività e processi - Gianpiero Data 2015-08-27T00:00:00+02:00 366.102

The Daschner Guide to In-Hospital Antibiotic Therapy - Uwe Frank 2012-01-24

Handy - concise - clear The "always on-hand" pocket guide to the treatment of infectious diseases. - The most important antibiotics and antimycotics: Spectrum - dosage - side-effects - Numerous tables sorted by substances, pathogens, indications - Administration of antibiotics during pregnancy, renal and hepatic insufficiency, dialysis - Including statements on the cost of therapy Numerous tips and troubleshooting guides on topics such as: - Potential mistakes - Therapy failures - Perioperative antibiotic prophylaxis Adjusted to European standards: Up-to-date substances, authorizations, resistances and trade names. The first guide to antibiotic therapy for Europe! All in all, an approach that looks towards the future in which antimicrobial resistance will certainly represent an ever-growing obstacle for the medical class, and for which books like this will undoubtedly represent a precious resource.

Giuseppe Cornaglia, MD, PhD President, European Society of Clinical Microbiology and Infectious Diseases (ESCMID) This book will most certainly be a valuable asset for all those treating patients with infections. While primarily aimed at the hospital setting, most of the very useful information can certainly be used in other healthcare settings, too. Andreas Voss Professor of Clinical Microbiology and Infection Control Radboud University Nijmegen Medical Centre and Canisius-Wilhelmina Hospital Nijmegen, The Netherlands

Health Care Cost, Quality, and Outcomes - Marc L. Berger 2003-01-01

"It includes over 100 entries covering more than 400 terms related to health care and the clinical, economic and patient-reported outcomes of that

care as well as to the overall management and regulation of health care."--P. xiii.

Hospital-Based Health Technology Assessment - Laura Sampietro-Colom 2017-01-23

A timely work describing how localized hospital-based health technology assessment (HB-HTA) complements general, 'arms-length' HTA agency efforts, and what has been the collective global impact of HB-HTA across the globe. While HB-HTA has gained significant momentum over the past few years, expertise in the field, and information on the operation and organization of HB-HTA, has been scattered. This book serves to bring this information together to inform those who are currently working in the field of HTA at the hospital, regional, national or global level. In addition, this book is intended for decision-makers and policy-makers with a stake in determining the uptake and decommissioning of new and established technologies in the hospital setting. HTA has traditionally been performed at the National/Regional level by HTA Agencies, typically linked to governments. Yet hospitals are the main entry door for most health technologies (HTs). Hospital decision-makers must undertake multiple high stakes investment and disinvestment decisions annually for innovative HTs, usually without adequate information. Despite the existence of arms-length HTA Agencies, inadequate information is available to hospital decision-makers either because relevant HTA reports are not yet released at the time of entry of new technologies to the field, or because even when the report exists, the information contained is insufficient to clarify the contextualized informational needs of hospital decision makers. Therefore, there has recently been a rising trend toward hospital-based HTA units and programs. These units/programs complement the work of National/Regional HTA Agencies by providing the key and relevant evidence needed by hospital decision makers in their specific hospital context, and within required decision-making timelines. The emergence of HB-HTA is creating a comprehensive HTA ecosystem across health care levels, which creates better bridges for knowledge translation through relevance and timeliness.

The Atlas of Health Inequalities in Japan - Tomoki Nakaya 2019-10-04

This new health atlas of Japan presents a series of maps about the health of the contemporary Japanese population, i.e. detailed maps of health indicators in small areas using cartograms. This is the first comprehensive small-area based health atlas about contemporary Japan using vital statistics from 1995-2014. Each map is supplemented with concise explanations written by leading epidemiologists and health geographers in Japan. The book employs various cutting-edge methods in spatial epidemiology, Bayesian spatial smoothing for the reliable mapping of mortality indices, advanced cartographic transformations using the concept of aerial cartograms, and summary statistics of socioeconomic health inequalities. The atlas highlights geographical aspects of social gradients in health by comparing mortality maps with distribution of deprivation index during the recent long-lasting economic stagnation period of Japan known as the lost decades. This health atlas will be a useful resource for international comparisons between Japan and other advanced countries in terms of health and related socioeconomic disparities between regions. It will be of interest to public health practitioners, administrators, researchers and students working on health geography and public health.

Annuario delle regioni - 1999

Healthcare Policies And Systems In Europe And China: Comparisons And Synergies - Mucelli Attilio 2017-11-27

Healthcare Policies and Systems in Europe and China, a product of an interdisciplinary European Union-funded project, comprehensively investigates opportunities for mutual integration in the healthcare sector of the two regions and analyses policies at both national and local levels, the legal environment, medical practices, as well as the state of respective healthcare industries and related businesses. The book sheds light on both the potential benefits and obstacles to the integration of Chinese and Western medicine, as well as practices and industries in Europe and China. An interdisciplinary approach is adopted throughout using tools and technical knowledge derived from the economics, social sciences, legal and medical fields. This edited volume seeks to provide guidelines and policy proposals

for policy-makers both in Europe and China, as well as offer operational suggestions for companies working in or with China, to enhance bilateral trade and investment flows. It also presents medical evidence and economic/legal analysis that will help boost the integration of traditional Chinese medicine with Western medicine through research studies. This is a recommended read for graduates, researchers and policy-makers seeking for a holistic understanding of healthcare policies and systems, both in theory and in practice.

Contents: Healthcare System and Industry in Europe and China: Common Issues and Future Opportunities: Relevance of Western Medicine and TCM in the Chinese and European Markets: An Overview (Attilio Mucelli) New Horizons of Chinese Healthcare System: Reforms and Perspectives (Daniela Caruso) Effect of Aging on Healthcare Industry's Cooperation Opportunities Between Europe and China (Dan Yang, Qinhong Wu and Attilio Mucelli) The Chinese TCM Industry: Growth, Changes and Policies (Marco R Di Tommaso, Manli Huang, Yue Qi and Chiara Pollio) Trade in Medical Products Between China and EU (Qu Ruxiao, Zeng Yanping and Liu Xia) The Healthcare Industry in the Chinese Economy: Insights from Input-Output Analysis (Noemi Ferracuti, Claudio Socci and Francesca Spigarelli) European Healthcare Industry and Chinese FDI: Where Do Chinese Firms Invest? (Ping Lv, Yu Liang and Francesca Spigarelli) Monopoly in the Chinese Healthcare Market: Norms and Practices (Lihong Zhang and Changmian Zhang) The Chinese Private Hospital Sector and FDI: From Socialization to Opening Up (Federica Monti) Investments, Research, Education, and TCM (Paolo Sospiro) The Integration of Western and Traditional Chinese Medicine: Challenges and Opportunities: Assessing Costs, Benefits, and Cost-Effectiveness in TCM (Attilio Mucelli and Olena Liakh) Evaluating the Use of TCM Through the Theory of Planned Behaviour: A Consumer Survey Analysis (Olena Liakh) Legal Framework on Health Foods in China and Food Supplements in the EU: A Comparison Study in the Perspective of TCM (Pamela Lattanzi and Qingle Hu) The Balance Between Patients' Choice and Economic Constraint in the Use of TCM Therapies: Two European Cases (Erik Longo and

Laura Vagni) Understanding Traditional Chinese Medicine from a Legal and Semantic Perspective (Saisai Wang and Kim Van der Borgh) Female Doctors in Ancient China: Comparative Studies Through Literature and Science (Elena Santilli) Traditional Chinese Medicine: Evidences from the Medical Field: Using International Perspective to Develop Traditional Chinese Medicine (Xiaolin Yuan and Xu Zhang) Cancer-Related Digestive Symptoms (Qijun Fang, Yujuan Wang and Tianshu Xu) Cancer-Related Fatigue (Qijun Fang, Yuj
Cancer in Pregnancy and Lactation - Gideon Koren 2011-11-10

Cancer in pregnancy presents physicians with a serious and ethical challenge, yet the sources of concise data and guidance for the management of this disease are scarce. The Motherisk program, based at the Hospital for Sick Children, Toronto, is dedicated to addressing this problem. *Cancer in Pregnancy and Lactation: The Motherisk Guide* tackles this subject by providing evidence-based information needed to address the complex issues of maternal diagnosis, management, treatment, prognosis and long-term impact on the unborn child. Based on the research by members of the international Consortium of Cancer in Pregnancy Evidence (CCoPE) this book provides physicians with the core knowledge required to make sound clinical decisions in the face of sometimes conflicting interests. Co-edited by recognized experts in the field with over 25 years' experience, this comprehensive volume is essential reading for all maternal-fetal medicine physicians, obstetricians, neonatologists, oncologists and pharmacologists.

Enciclopedia medica italiana. 3. aggiornamento della seconda edizione - 2008

Evidence-Based Health Economics - Miranda Mugford 2014-05-28

This text recognises the need for evidence-based principles in economic evaluation, and that they should be based themselves on health economics. It discusses systematic review in economic analysis and suggests how to perform analyses in an evidence-based way.

Accrescere l'efficacia degli interventi.

L'esperienza delle linee guida diagnostico-terapeutiche e la regolazione del settore

farmaceutico - C. Collicelli 1999

L'economia delle aziende farmaceutiche. Caratteri strutturali, operativi e modelli di corporate governance - Ascensionato Raffaello Carnà 2007

Elementi di clinical governance in pneumologia - Davide Croce 2010

Riflessioni sulla Bioetica - Arturo Mapelli
2015-07-14

Uno straordinario patrimonio, culturale, professionale e di umanità costituisce la base di questa raccolta di articoli sulla bioetica. Il presente volume è costituito dalla raccolta di articoli comparsi sul settimanale "il Ticino" dal 2006 al 2012 nella rubrica "Bioetica oggi". Si tratta di riflessioni riguardanti le problematiche di più scottante attualità nell'ambito dell'Etica applicata alla Biologia ed in particolare alla Medicina. La trattazione dei temi non è organica né sistematica: per questo si rimanda ai trattati e alle pubblicazioni, sempre più numerose, sulla Bioetica. Da tale letteratura, nonché dall'attualità e da alcuni fatti di cronaca, sono stati presi gli spunti per le riflessioni contenute in questa raccolta. Esse riguardano le varie fasi della vita dell'uomo (nascere, vivere e morire), si fondano su una visione antropologica ispirata al Cristianesimo e sono rivolte agli operatori sanitari, agli studenti, ai volontari e a tutti coloro che sono sensibili ai problemi etici della biologia e della medicina, clinica e scientifica.

Riforma medica - 1993

L'industria, rivista di economia e politica industriale - 1997

Governo clinico e medicina perioperatoria - Antonino Gullo 2012-11-06

Per governo clinico si intende la capacità di gestione del sistema sanitario, caratterizzato, come noto, da una notevole complessità. Gli obiettivi di questa gestione si articolano su numerosi fronti di sviluppo, tra cui il miglioramento delle prestazioni assistenziali, la riduzione degli errori in medicina, la garanzia della sicurezza per i pazienti, l'appropriatezza nel decision making in tema di salute, il controllo del livello di competenza del personale, fino al

controllo delle risorse disponibili e dei costi di gestione. Questo volume affronta gli aspetti che gravitano attorno al governo clinico e alla sua introduzione in settori cardine quali l'anestesia e la medicina del malato critico. Dopo una prima sezione dedicata alle good practices, al professionalismo e al ruolo dell'errore in medicina, la trattazione affronta nel dettaglio numerose questioni di grande rilevanza nel perioperatorio: etica e deontologia, costi, procedure e audit, organizzazione del team, monitoraggio del dolore in età pediatrica, fino a importanti considerazioni sul punto di vista del paziente. Completano il volume una sezione sul ruolo della ricerca clinica e un glossario. Caratterizzato da una particolare completezza e varietà di argomenti, questo testo vuole offrire ai diversi professionisti e operatori del settore indicazioni utili ed efficaci su come articolare l'organizzazione del sistema sanitario moderno.

Costi sociali e aspetti farmacoeconomici - M.P. Amato 2005-09-19

La sclerosi multipla (SM) rappresenta la seconda causa di disabilità neurologica nel giovane adulto, dopo i traumi cranici. Negli ultimi anni, l'introduzione di nuovi farmaci, potenzialmente in grado di modificare il decorso della malattia, ha richiamato l'attenzione sui costi sociali della SM e sugli aspetti farmaco-economici. Si sono avanziati, da un lato, timori che il costo dei nuovi farmaci costituisca un onere insostenibile per il sistema sanitario. Dall'altro lato, recenti studi economici hanno sottolineato l'importanza di una valutazione inserita in una prospettiva più ampia, considerando la possibilità che le nuove terapie possano ridurre i costi sociali di malattia nel lungo termine, ritardando o evitando lo sviluppo di invalidità. Questo volume rivede la letteratura internazionale sui costi sociali della SM, e gli studi farmaco-economici sui nuovi farmaci per la malattia. In futuro, sarà necessario implementare studi metodologicamente rigorosi, in particolare di tipo comparativo. Estremamente importante sarà la raccolta di dati prospettici su ampie popolazioni di pazienti, per valutare il reale impatto delle nuove terapie sullo sviluppo di disabilità a lungo termine. Le informazioni attualmente disponibili derivano infatti essenzialmente dalle sperimentazioni terapeutiche, che si riferiscono a casistiche

selezionate di pazienti seguiti per brevi periodi (2-3 anni). L'acquisizione di questi dati sarà di importanza critica per migliorare la stima del rapporto costi/benefici con l'impiego dei nuovi farmaci e valutare le priorità in politica sanitaria negli anni a venire.

Is It Tomorrow Yet? - Ivan Krastev 2020-10-29
A FINANCIAL TIMES BOOK OF THE YEAR One of our most scintillating public intellectuals explores the political paradoxes of the pandemic and helps us think our way through it 'We are able to imagine anything because we are being besieged by something that was considered unimaginable...' Beneath the panic and bluster, beneath the confusing speeches and the conflicting advice, the Coronavirus pandemic acted, changing our world in the most profound

ways. The tragic human cost and the economic devastation will be assessed and calculated for decades to come. But the pandemic also changed things in ways that are less easily expressed and understood. It has made bare the frayed contradictions of modern life. It has distorted things that seemed simple and settled. It has affirmed plain, uncomfortable truths. In this brilliant, thought-provoking essay, Ivan Krastev, one of our most interesting thinkers today, explores the pandemic's immediate consequences and conceives of its long-term legacy. Will things be different for the communities most harmed, and for those who escaped the worst? Where are we now with the US and China, with the UK and Europe? And how do we think our way through the unthinkable?